soluble TNF receptor 1 (sTNF RI) serum
Test Code: 30144
Cpt Code:84238 (x1)
For the quantitative measurement of soluble Tumor Necrosis Factor receptor 1 (sTNFR1). The pro-inflammatory cytokine, TNFα and its soluble receptor, sTNFR1, are potent modulators of the inflammatory process.
The assay for quantification of sTNFR1 is a sandwich ELISA performed in a microtiter plate format. Conversion of a chromogenic substrate produces a color, the intensity of which is proportional to the concentration of sTNFR1 in the sample material. A standard curve is used to calculate the concentration of sTNFR1 in each of the test samples. This test has not been cleared or approved for diagnostic use by the U.S. Food and Drug Administration.
Specific to human sTNFR1.
The result is reported in ng/mL. The assay range is approximately 0.2 to 16 ng/mL. The reference range for a healthy population is less than 2.4 ng/mL. However it should be noted that these ranges are obtained from a limited population of apparently healthy adults and are not diagnostic thresholds.
Causes For Rejection
Invalid specimen type, inadequate volume, gross hemolysis or gross lipemia, sample not frozen upon receipt.
Test performed M,W,F. TAT 3 - 5 days from receipt of specimen.
Ship Monday through Friday. Friday shipments must be labeled for Saturday delivery. All specimens must be labeled with patient's name and collection date. A Viracor-IBT test requisition form must accompany each specimen. Multiple tests can be run on one specimen. Ship specimens FedEx Priority Overnight® to: Viracor-IBT Laboratories, 1001 NW Technology Dr, Lee's Summit, MO 64086.
NY approved. Whole blood should be collected in serum tube, allowed to clot for 30 to 60 minutes and centrifuged to isolate the serum. 1 mL of serum should be removed to a sterile tube and frozen immediately (-70°C).
Specimens are approved for testing in New York only when indicated in the Specimen Information field above.
The CPT codes provided are based on Viracor-IBT's interpretation of the American Medical Association's Current Procedural Terminology (CPT) codes and are provided for general informational purposes only. CPT coding is the sole responsibility of the billing party. Questions regarding coding should be addressed to your local Medicare carrier. Viracor-IBT assumes no responsibility for billing errors due to reliance on the CPT codes illustrated in this material.
August, KJ, KY Chiang, RM Bostick, WE Flanders, EK Waller, A Langston, D Worthington-White, P Rowland, KF Moore, HJ Khoury and JT Horan. 2011. Biomarkers of immune activation to screen for severe, acute GVHD. Bone Marrow Transpl 46: 601-604.
dePablo, R, J Monserrat, E Reyes, D Diaz-Martin, MR Zapata, F Carballo, A de la Hera, A Prieto and M Alvarez-Mon. 2011, Mortality in patients with septic shock correlates with anti-inflammatory but not proinflammatory immunomodulatory molecules. J Intensive Care Med 26(2): 125-132.
Sakata, N, M Yasui, T Okamura, M Inoue, K yumura-Yagi and K Kawa. 2001. Kinetics of plasma cytokines after hematopoietic stem cell transplantation from unrelated donors: the ratio of plasma IL-10/sTNFR level as a potential prognostic marker in severe acute graft-versus-host disease.
Spoettl, T, M Hausmann, F Klebl, A Dirmeier, B Klump, J Hoffmann, H Herfarth, A Timmer, G Rogler. 2007. Serum soluble TNF receptor I and II levels correlate with disease activity in IBD patients. Inflamm Bowel Dis. 13(6): 727-732.
Glossop, JR, PT DSawes, NB Nixon, DL Mattey. 2005. Polymorphism in the tumour necrosis factor receptor II gene is associated with circulating levels of soluble tumour necrosis factor receptors in rheumatoid arthritis. Arthritis Res Ther 7(6): R1227-1234.
Majewski, S, A Wojas-Pelc, M Malejczyk, E Szymanska and S Jablonska. 1999. Serum levels of soluble TNF alpha receptor type I and the severity of systemic sclerosis. Acta Derm Venereol 79(3): 207-210.
Choi SW, P Stiff, K Cooke, JLM Ferrara, T Braun, C Kitko, P Reddy , G Yanik, S Mineishi, S paczesny, D Hanauer, A Pawarode, E Peres, T Rodriguez, S Smith and JE Levine. 2012. TNF-Inhibition with Etanercept for Graft-versus-Host disease prevention in high risk HCT: Lower TNFRI levels correlate with better outcomes. Biol Blood Marrow Transplant: Biol Blood Marrow Transpl 18: 1517-1524.
Paczesny, S, OI Krijanovski, TM Braun, SW Choi, SG Clouthier, R Kuick, DE Misek, KR Cooke, CL Kitko, A Weyand, D Bickley, D Jones, J Whitfield, P Reddy, JE Levine, SM Hanash and JLM Ferrara. 2009. A biomarker panel for acute graft-versus-host disease. Blood 113(2): 273-278.
John E. Levine, Brent R. Logan, Juan Wu, Amin M. Alousi, Javier Bolaños-Meade, James L.M. Ferrara, Vincent T. Ho, Daniel J. Weisdorf and Sophie Paczesny (2012) Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study. Blood. 119(16):3854-3860.